Home » Stocks » PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc. (PHAS)

Stock Price: $3.66 USD 0.22 (6.40%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 107.40M
Revenue (ttm) 1.33M
Net Income (ttm) -65.77M
Shares Out 29.34M
EPS (ttm) -2.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $3.66
Previous Close $3.44
Change ($) 0.22
Change (%) 6.40%
Day's Open 3.49
Day's Range 3.45 - 3.70
Day's Volume 200,402
52-Week Range 2.60 - 8.49

More Stats

Market Cap 107.40M
Enterprise Value n/a
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.34M
Float 15.40M
EPS (basic) n/a
EPS (diluted) -2.29
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.83M
Short Ratio 16.84
Short % of Float 24.85%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 81.05
PB Ratio 3.82
Revenue 1.33M
Operating Income n/a
Net Income -65.77M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin -2,154.72%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.51%
ROE -121.79%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.73*
(193.17% upside)
Low
3.91
Current: $3.66
High
18.00
Target: 10.73
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name PhaseBio Pharmaceuticals, Inc.
Country United States
Employees 50
CEO Jonathan P. Mow

Stock Information

Ticker Symbol PHAS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PHAS
IPO Date October 18, 2018

Description

PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.